Suppr超能文献

通过综合生物信息学分析方法鉴定CDCA4为结直肠癌放疗抵抗相关基因。

Identifying CDCA4 as a Radiotherapy Resistance-Associated Gene in Colorectal Cancer by an Integrated Bioinformatics Analysis Approach.

作者信息

Chen Lin, Gao Yawei, Hu Zhiqing, Si Jingwen, Zhang Yuchao, Cai Qingping

机构信息

Department of Gastrointestinal Surgery, Department of General Surgery, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200120, China.

Department of Gastrointestinal Surgery, Department of General Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.

出版信息

Genes (Basel). 2025 Jun 9;16(6):696. doi: 10.3390/genes16060696.

Abstract

BACKGROUND

Colorectal cancer (CRC) remains one of the most prevalent and fatal malignancies globally, with radiotherapy playing a crucial role in the treatment of locally advanced rectal cancer (LARC). However, the efficacy of radiotherapy is limited by significant resistance, with only a small proportion of patients achieving a pathologic complete response (PCR) to neoadjuvant chemoradiotherapy (nCRT). This study aims to uncover the genetic and molecular factors contributing to radiotherapy resistance in CRC through an integrated analysis of germline mutations, transcriptomic data, and immune microenvironment characteristics.

METHODS

Whole-exome sequencing (WES) was performed on tumor samples from 12 LARC patients. Transcriptomic data from the TCGA-READ and GSE150082 (LARC with chemoradiotherapy) cohorts were integrated with WES findings. The independent cohort GSE190826 (neoadjuvant therapy in rectal cancer) dataset was utilized to validate the WES data. Single-cell RNA sequencing (scRNA-seq) analysis of GSE132465 (primary CRC) resolved cellular heterogeneity. A random forest algorithm was employed to develop a predictive gene signature.

RESULTS

Our findings reveal a mutational landscape associated with radiotherapy resistance, identifying specific germline mutations linked to treatment outcomes. Differential gene expression analysis highlighted pathways involved in DNA replication, DNA repair, and immune regulation, with a focus on the tumor immune microenvironment (TIME). A gene signature, including CDCA4, FANCA, PBRM1, RPL13, and C12orf43, was developed to predict radiotherapy response. Notably, CDCA4 expression was significantly associated with tumor mutation burden (TMB) and microsatellite instability (MSI), and it plays a crucial role in regulating B cell infiltration in the tumor microenvironment.

CONCLUSIONS

Our study provides novel insights into the molecular mechanisms of radiotherapy resistance in CRC and proposes CDCA4 and B cell-related immune features as potential biomarkers for patient stratification and personalized treatment strategies.

摘要

背景

结直肠癌(CRC)仍是全球最常见且致命的恶性肿瘤之一,放疗在局部晚期直肠癌(LARC)的治疗中起着关键作用。然而,放疗的疗效受到显著抗性的限制,只有一小部分患者对新辅助放化疗(nCRT)达到病理完全缓解(PCR)。本研究旨在通过对种系突变、转录组数据和免疫微环境特征的综合分析,揭示导致CRC放疗抗性的遗传和分子因素。

方法

对12例LARC患者的肿瘤样本进行全外显子组测序(WES)。来自TCGA-READ和GSE150082(接受放化疗的LARC)队列的转录组数据与WES结果进行整合。利用独立队列GSE190826(直肠癌新辅助治疗)数据集验证WES数据。对GSE132465(原发性CRC)进行单细胞RNA测序(scRNA-seq)分析以解析细胞异质性。采用随机森林算法开发预测基因特征。

结果

我们的研究结果揭示了与放疗抗性相关的突变图谱,确定了与治疗结果相关的特定种系突变。差异基因表达分析突出了参与DNA复制、DNA修复和免疫调节的通路,重点关注肿瘤免疫微环境(TIME)。开发了一个包括CDCA4、FANCA、PBRM1、RPL13和C12orf43的基因特征来预测放疗反应。值得注意的是,CDCA4表达与肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)显著相关,并且在调节肿瘤微环境中的B细胞浸润中起关键作用。

结论

我们的研究为CRC放疗抗性的分子机制提供了新的见解,并提出CDCA4和B细胞相关免疫特征作为患者分层和个性化治疗策略的潜在生物标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验